ATE381626T1 - Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel - Google Patents
Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittelInfo
- Publication number
- ATE381626T1 ATE381626T1 AT01926956T AT01926956T ATE381626T1 AT E381626 T1 ATE381626 T1 AT E381626T1 AT 01926956 T AT01926956 T AT 01926956T AT 01926956 T AT01926956 T AT 01926956T AT E381626 T1 ATE381626 T1 AT E381626T1
- Authority
- AT
- Austria
- Prior art keywords
- genes
- prolonged
- adverse reaction
- genetic
- prolongation
- Prior art date
Links
- 206010067484 Adverse reaction Diseases 0.000 title abstract 2
- 230000006838 adverse reaction Effects 0.000 title abstract 2
- 238000003745 diagnosis Methods 0.000 title abstract 2
- 239000003814 drug Substances 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 230000002068 genetic effect Effects 0.000 title 1
- 108090000623 proteins and genes Proteins 0.000 abstract 4
- 230000002035 prolonged effect Effects 0.000 abstract 3
- 208000018452 Torsade de pointes Diseases 0.000 abstract 2
- 208000002363 Torsades de Pointes Diseases 0.000 abstract 2
- 230000035772 mutation Effects 0.000 abstract 2
- 239000008177 pharmaceutical agent Substances 0.000 abstract 2
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 abstract 1
- 206010071602 Genetic polymorphism Diseases 0.000 abstract 1
- 101000974720 Homo sapiens Potassium voltage-gated channel subfamily E member 2 Proteins 0.000 abstract 1
- 108700041567 MDR Genes Proteins 0.000 abstract 1
- 102100022752 Potassium voltage-gated channel subfamily E member 2 Human genes 0.000 abstract 1
- 238000012252 genetic analysis Methods 0.000 abstract 1
- 238000010448 genetic screening Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 102000054765 polymorphisms of proteins Human genes 0.000 abstract 1
- 230000035945 sensitivity Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Analytical Chemistry (AREA)
- Wood Science & Technology (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Pathology (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US19691600P | 2000-04-13 | 2000-04-13 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE381626T1 true ATE381626T1 (de) | 2008-01-15 |
Family
ID=22727270
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01926956T ATE381626T1 (de) | 2000-04-13 | 2001-04-13 | Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US7179597B2 (de) |
| EP (1) | EP1290220B1 (de) |
| AT (1) | ATE381626T1 (de) |
| DE (1) | DE60131970T2 (de) |
| WO (1) | WO2001079554A1 (de) |
Families Citing this family (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2449752A1 (en) * | 2001-06-05 | 2002-12-12 | Genaissance Pharmaceuticals, Inc. | Method of identifying a polymorphism in cyp2d6 |
| US8263375B2 (en) | 2002-12-20 | 2012-09-11 | Acea Biosciences | Dynamic monitoring of activation of G-protein coupled receptor (GPCR) and receptor tyrosine kinase (RTK) in living cells using real-time microelectronic cell sensing technology |
| US7192752B2 (en) | 2002-12-20 | 2007-03-20 | Acea Biosciences | Real time electronic cell sensing systems and applications for cell-based assays |
| US10215748B2 (en) | 2002-12-20 | 2019-02-26 | Acea Biosciences, Inc. | Using impedance-based cell response profiling to identify putative inhibitors for oncogene addicted targets or pathways |
| US10539523B2 (en) | 2002-12-20 | 2020-01-21 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology, and electrophysiological properties |
| US11346797B2 (en) | 2002-12-20 | 2022-05-31 | Agilent Technologies, Inc. | System and method for monitoring cardiomyocyte beating, viability, morphology and electrophysiological properties |
| US10551371B2 (en) | 2003-11-10 | 2020-02-04 | Acea Biosciences, Inc. | System and method for monitoring cardiomyocyte beating, viability and morphology and for screening for pharmacological agents which may induce cardiotoxicity or modulate cardiomyocyte function |
| US20100063093A1 (en) * | 2007-03-28 | 2010-03-11 | Curt Wolfgang | Methods for the administration of iloperidone |
| CA3113166A1 (en) | 2004-09-30 | 2006-04-13 | Vanda Pharmaceuticals Inc. | Methods for the administration of iloperidone |
| AU2006315760A1 (en) * | 2005-11-10 | 2007-05-24 | Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Materials and methods for ABCB1 polymorphic variant screening, diagnosis, and treatment |
| US20080140371A1 (en) * | 2006-11-15 | 2008-06-12 | General Electric Company | System and method for treating a patient |
| WO2009137440A1 (en) | 2008-05-05 | 2009-11-12 | Acea Biosciences, Inc. | Label-free monitoring of excitation-contraction coupling and excitable cells using impedance based systems with millisecond time resolution |
| EP2356233A2 (de) * | 2008-11-13 | 2011-08-17 | EUCRO European Contract Research GmbH & Co. KG | Verfahren zum sammeln von mundschleimhautzellen und/oder -zellfragmenten |
| US8315815B2 (en) | 2008-12-30 | 2012-11-20 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| US8321151B2 (en) | 2008-12-30 | 2012-11-27 | The Invention Science Fund I, Llc | Computational methods and systems for treatment in relation to modulation of CYP450 enzyme activity |
| US8073633B2 (en) * | 2008-12-30 | 2011-12-06 | The Invention Science Fund I, Llc | Computational methods and systems for suggesting modulators of CYP450 as treatment options |
| EP2417266B1 (de) | 2009-04-06 | 2016-03-09 | Vanda Pharmaceuticals Inc. | Verfahren zur prognose einer prädisposition für qt-verlängerung |
| CA2757723C (en) | 2009-04-06 | 2018-07-24 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to qt prolongation based on abcc2 gene sequence or product thereof |
| HUE037724T2 (hu) | 2009-04-06 | 2018-09-28 | Vanda Pharmaceuticals Inc | Eljárás a KCNQ1 gén polimorfizmusán alapuló kezelésre |
| US9072742B2 (en) | 2009-04-06 | 2015-07-07 | Vanda Pharmaceuticals, Inc. | Method of predicting a predisposition to QT prolongation |
| KR101251538B1 (ko) | 2009-04-17 | 2013-04-08 | (주)아벨리노 | 아벨리노 각막이상증 진단용 프라이머 |
| WO2011146531A1 (en) * | 2010-05-18 | 2011-11-24 | Acea Biosciences, Inc | Data analysis of impedance-based cardiomyocyte-beating signals as detected on real-time cell analysis (rtca) cardio instruments |
| KR101125212B1 (ko) | 2010-10-01 | 2012-03-21 | (주)아벨리노 | 아벨리노 각막이상증 진단용 시스템 |
| WO2012149406A2 (en) * | 2011-04-29 | 2012-11-01 | Mayo Foundation For Medical Education And Research | Assessing and treating humans with long qt syndrome |
| KR20220100079A (ko) * | 2013-03-15 | 2022-07-14 | 아벨리노 랩 유에스에이, 인크. | 대립유전자 검출을 위한 게놈 dna 주형의 개선된 단리 방법 |
| US10889850B2 (en) | 2013-03-15 | 2021-01-12 | Avellino Lab Usa, Inc. | Methods for improved isolation of genomic DNA templates for allele detection |
| EP3068908B1 (de) | 2013-11-15 | 2021-01-06 | Avellino Lab USA, Inc. | Verfahren zum multiplexnachweis von mit augenleiden assoziierten allelen |
| DE102014209627B3 (de) * | 2014-05-21 | 2015-10-29 | Cytocentrics Bioscience Gmbh | In-Vitro-Diagnostik für die modellgestützte Therapieplanung |
| EP4036228A1 (de) | 2015-11-13 | 2022-08-03 | Avellino Lab USA, Inc. | Verfahren zur behandlung von hornhautdystrophien |
| US12066428B2 (en) | 2015-11-20 | 2024-08-20 | Agilent Technologies, Inc. | Cell-substrate impedance monitoring of cancer cells |
| KR101920994B1 (ko) * | 2016-06-14 | 2018-11-21 | 서울대학교산학협력단 | 식물의 수액 유속 측정용 마이크로 니들 프로브 장치 및 이를 이용한 식물의 수액 유속 측정 방법 |
| EP4549553A3 (de) | 2017-03-03 | 2025-07-16 | Agilent Technologies, Inc. | Verfahren und systeme zur funktionellen reifung von kardiomyozyten aus ipsc und esc |
| US10799138B2 (en) | 2018-04-05 | 2020-10-13 | University Of Maryland, Baltimore | Method of administering sotalol IV/switch |
| US11696902B2 (en) | 2018-08-14 | 2023-07-11 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US12396970B2 (en) | 2021-08-20 | 2025-08-26 | AltaThera Pharmaceuticals LLC | Anti-arrhythmic compositions and methods |
| US11344518B2 (en) | 2018-08-14 | 2022-05-31 | AltaThera Pharmaceuticals LLC | Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame |
| US10512620B1 (en) | 2018-08-14 | 2019-12-24 | AltaThera Pharmaceuticals, LLC | Method of initiating and escalating sotalol hydrochloride dosing |
| US11610660B1 (en) | 2021-08-20 | 2023-03-21 | AltaThera Pharmaceuticals LLC | Antiarrhythmic drug dosing methods, medical devices, and systems |
| USD941488S1 (en) | 2020-02-07 | 2022-01-18 | Agilent Technologies, Inc. | Instrument for analyzing biological cells |
| US20210301245A1 (en) | 2020-03-29 | 2021-09-30 | Agilent Technologies, Inc. | Systems and methods for electronically and optically monitoring biological samples |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5599673A (en) * | 1995-03-09 | 1997-02-04 | University Of Utah Research Foundation | Long QT syndrome genes |
| US6277978B1 (en) | 1995-12-22 | 2001-08-21 | University Of Utah Research Foundation | KVLQT1—a long QT syndrome gene |
| US6432639B1 (en) * | 1997-09-10 | 2002-08-13 | Dna Sciences Laboratories, Inc. | Isolated CYP3A4 nucleic acid molecules and detection methods |
| US6207383B1 (en) * | 1998-07-27 | 2001-03-27 | University Of Utah Research Foundation | Mutations in and genomic structure of HERG—a long QT syndrome gene |
-
2001
- 2001-04-13 AT AT01926956T patent/ATE381626T1/de not_active IP Right Cessation
- 2001-04-13 US US10/257,573 patent/US7179597B2/en not_active Expired - Fee Related
- 2001-04-13 WO PCT/US2001/012087 patent/WO2001079554A1/en not_active Ceased
- 2001-04-13 DE DE60131970T patent/DE60131970T2/de not_active Expired - Lifetime
- 2001-04-13 EP EP01926956A patent/EP1290220B1/de not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| EP1290220A4 (de) | 2004-09-22 |
| DE60131970T2 (de) | 2008-12-11 |
| DE60131970D1 (de) | 2008-01-31 |
| EP1290220B1 (de) | 2007-12-19 |
| WO2001079554A1 (en) | 2001-10-25 |
| EP1290220A1 (de) | 2003-03-12 |
| US7179597B2 (en) | 2007-02-20 |
| US20030211500A1 (en) | 2003-11-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE381626T1 (de) | Genetische diagnose zur feststellung von qt- verlängerungen als unerwünschte reaktion auf arzneimittel | |
| Burnett et al. | Population-based toxicity screening in human induced pluripotent stem cell-derived cardiomyocytes | |
| Li et al. | Association analysis of the dopamine D4 gene exon III VNTR and heroin abuse in Chinese subjects | |
| Liu et al. | Evidence for a putative bipolar disorder locus on 2p13–16 and other potential loci on 4q31, 7q34, 8q13, 9q31, 10q21–24, 13q32, 14q21 and 17q11–12 | |
| Kohn et al. | Dopamine D4 receptor gene polymorphisms: relation to ethnicity, no association with schizophrenia and response to clozapine in Israeli subjects | |
| Marsh | Pyrosequencing® applications | |
| Sagvolden et al. | Behavioral and genetic evidence for a novel animal model of Attention-Deficit/Hyperactivity Disorder Predominantly Inattentive Subtype | |
| Crisafulli et al. | Case–control association study for 10 genes in patients with schizophrenia: influence of 5HTR1A variation rs10042486 on schizophrenia and response to antipsychotics | |
| Becker et al. | Evidence for differences in DNA methylation between Germans and Japanese | |
| Bis et al. | Uniparental disomy determined by whole‐exome sequencing in a spectrum of rare motoneuron diseases and ataxias | |
| Umair et al. | First direct evidence of involvement of a homozygous loss‐of‐function variant in the EPS15L1 gene underlying split‐hand/split‐foot malformation | |
| Clark et al. | Dual methylation and hydroxymethylation study of alcohol use disorder | |
| Dertinger et al. | High information content assays for genetic toxicology testing: A report of the International Workshops on Genotoxicity Testing (IWGT) | |
| Koo et al. | Pharmacogenetics approach to therapeutics. | |
| Morling | PCR in forensic genetics | |
| Tomita-Mitchell et al. | Single nucleotide polymorphism spectra in newborns and centenarians: identification of genes coding for rise of mortal disease | |
| FR2793809B1 (fr) | Procede d'analyse de la predisposition genetique d'un patient a au moins une maladie et amplification adaptee a un tel procede | |
| Airey et al. | Variation in the cortical area map of C57BL/6J and DBA/2J inbred mice predicts strain identity | |
| ATE376066T1 (de) | Verfahren zur abschätzung der sensitivität für osteoporose-medikamente | |
| Izzi et al. | Sequencing of the GRIK1 gene in patients with juvenile absence epilepsy does not reveal mutations affecting receptor structure | |
| Ben et al. | Multiplex SNaPshot—a new simple and efficient CYP2D6 and ADRB1 genotyping method | |
| Berger et al. | Effect of nivasorexant (ACT‐539313), a selective orexin‐1‐receptor antagonist, on multiple cytochrome P450 probe substrates in vitro and in vivo using a cocktail approach in healthy subjects | |
| Verbist et al. | Integrating high-dimensional transcriptomics and image analysis tools into early safety screening: Proof of concept for a new early drug development strategy | |
| Gwinn et al. | Amyotrophic lateral sclerosis: an emerging era of collaborative gene discovery | |
| DE69710469D1 (de) | Diagnoseverfahren und vorrichtung zum nachweis der prädisposition zu bestimmten krankheitszuständen, insbesondere osteoporose, auf basis von il-6 genpolymorphismus |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |